Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party..

Post time 2024-4-29 17:46:41

journal：American Journal of Hematology

Authors：Yishan Ye; Myriam Labopin; Socié Gérard; Ibrahim Yakoub‐Agha; Igor Wolfgang Blau; Mahmoud Aljurf; Edouard Forcade; Tobias Gedde‐Dahl; David Burns; Jan Vydra; Khalid Halahleh; Rose‐Marie Hamladji; Ali Bazarbachi; Arnon Nagler; Eolia Brissot; Lin Li; Yi Luo; Yanmin Zhao; Fabio Ciceri; He Huang; Mohamad Mohty; Norbert Claude Gorin

Published date：--

DOI：10.1002/ajh.27342

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27342

Article link：http://dx.doi.org/10.1002/ajh.27342

Article Source：Wiley。

Remark：

Post time 2024-4-29 17:46:42

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party..

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party.. Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party..